Free Trading + Demat Account

IPO Discussion Page

Please Note: All views and opinions expressed in reader comments are solely those of the individual submitting the comment, and not those of the or its staff.

bangalore king's Comments

Close bangalore king's Comments


9. bangalore king  Jan 5, 2017 12:25:38 PM IST Reply

BSE Limited IPO


Maintain overweight, raise target to `385 from `365

See lower rates and pickup in financial savings since demonetization

Co has likely steady persistency trends helped by zero cash collections

Short-term growth moderation possible in credit life premiums following lower home loan sales

Co has balanced distribution mix, rising protection mix, improving persistency/costs

See multiyear improvement in profitability leading to strong VNB CAGR during F16-F19
8. bangalore king  Dec 19, 2016 6:17:42 PM IST Reply

Laurus Labs Ltd IPO

NOMURA INDIA INVESTMENT FUND MOTHER FUND bought 7,35,000 shares at 477.5 ..
7. bangalore king  Dec 5, 2016 8:42:11 PM IST Reply

Laurus Labs Ltd IPO

Anchor list
6. bangalore king  Dec 3, 2016 7:11:47 PM IST Reply

Laurus Labs Ltd IPO

I see lot of boarders are giving crazy target on this IPO listing.. The fundamentals are strong but market is uncertain and valuation are higher. So it may not get listed with high premiums.

Shares will be deposited in demat on December 15 and listing may take place on December 16 around Rs450/460 and may cross Rs475 in favorable
condition. It may give five-seven per cent gain on listing.

The investors can subscribe the issue with 2-3 year outlook.
5. bangalore king  Dec 1, 2016 10:54:34 PM IST Reply

Laurus Labs Ltd IPO

For FY 2016, Laurus Labs had basic earnings per share (EPS) of INR20.86 while diluted EPS stood at INR13.48 on a consolidated basis. The price band of INR426 – 428 per share values the company at a PE ratio of 31.6 – 31.75. These are rich valuations considering sub-30 figures for listed peers like Aurobindo Pharma and Divis Laboratories.
5.1. ShareView  Dec 2, 2016 11:02:52 AM IST

Laurus Labs Ltd IPO

Dear Experts ,
w.r.t P/E , This point is remarkable.
Divis Lab is trading @ 29 p/e &
Auropharma trading @ 22 p/e
Co. specified in the ''basis of issue price''

No doubt Issue is good for listing gain
But does it justify for long term ?

We would be grateful for your reply
4. bangalore king  Nov 28, 2016 8:18:11 PM IST Reply

Sheela Foam Ltd IPO

Anchor allocation -
3. bangalore king  Nov 26, 2016 11:25:12 PM IST Reply

Sheela Foam Ltd IPO

original share price for the main promoter Sheela Gautam
is just 3 paisa per share, for Rahul Gautam it is 12 paisa and for selling shareholders
it is just 33 paisa per share, while offer price is Rs730.
- Before filling DRHP, the promoters have issued bonus shares in ratio of 2:1.
- In the resolution passed on May 31, 2016, the face value of the share has been
brought down to Rs 5 from Rs10. If they had not done so the IPO offer price could
have been Rs1460, so they have tried to misguide the investors even before filling
- Before entering into the market the net profit has surged 146% in FY2016. While
the income growth has come down from 11.23 in FY2015 to 9.20% in FY2016. So
it creates doubts about authenticity of the figures.
- Raw material accounts for 50-60% in the company''s income. It used to get benefit
of rockbottom prices in last few years. So the current margins are low but difficult
to maintain.
- The sales is under pressure due to demonetization. After Poor Listing of Varun
Beverages and Flop show of Green Signal Bio Pharma, will the investors ready to
take risk?
- The experts in the market expect the IPO to get listed at discount and also indicated
that deal is done with QIB and HNI investors so they are list bothered about
retail investors. So the main question is that Is the issue worth subscribing?
3.1. dpcdsl  Nov 26, 2016 11:56:28 PM IST

Sheela Foam Ltd IPO

Good analysis.
3.2. jigaReligare  Nov 27, 2016 7:50:07 AM IST

Sheela Foam Ltd IPO

thanks for info
2. bangalore king  Nov 21, 2016 12:05:15 AM IST Reply

Sheela Foam Ltd IPO

Shareholders can subscribe to the rights issue of Karnataka Bank, the price for which has been fixed at ₹70 per share. Open until November 21, the issue of shares will be done in the ratio of 1:2 — one rights share for every two held by the shareholders.

Though the bank has seen sluggish growth in loans over the last two to three years and has also had to deal with rising bad loans, prospects over the long run appear sanguine.

The price of the rights issue is at a huge discount to the current market price of ₹121 (ex-rights). If the price holds up, there is scope for immediate gains. But that’s only the icing on the cake.

For long-term investors, the bank’s earnings trajectory and growth prospects should be the deciding factor for subscribing to the rights issue.

In this regard, the bank’s strong regional presence, conscious decision to cut back on corporate credit, increased focus on retail loans and stable margins augur well for its earnings outlook over the next two to three years. At 0.7 times the one-year forward book, the stock trades in line with its three-and five-year average.

Compared to other regional banks such as South Indian Bank (0.7 times) and Federal Bank (1.4 times), the stock is attractively priced. Pick-up in earnings on account of easing asset quality pressure and improving credit growth can see the stock re-rate over the next two to three years.
2.1. RAJA HINDUSTANI  Nov 22, 2016 7:15:04 PM IST

Sheela Foam Ltd IPO

But Why have they Extended ? Is it under subscribed ??
1. bangalore king  Nov 8, 2016 3:48:31 PM IST Reply

GreenSignal Bio Pharma Ltd IPO

2 products, 2 customers !!!

FY16 sales: Rs 20.39 crore, equity capital: 38.37 crore

The company posted an inconsistent top line, with losses for FY 2012 to FY 2015 largely due to ongoing investments and inability to win key tenders as also reduced orders from Cadila Healthcare.

For the June 2016 quarter, the company reported net sales of Rs 10.15 crore with the OPM of 40.3% resulted in an OP of Rs 4.09 crore. Interest costs stood at Rs 0.66 crore and depreciation at Rs 1.19 crore. After providing total tax of Rs 0.79 crore, PAT for the June 2016 quarter stood at Rs 2.94 crore. EPS for the June 2016 quarter is not annualized due to the seasonality of business.

For FY 2016, the net sales were up by 211% to Rs 20.39 crore. The OPM stood at 42.6% as compared to 27.6% for FY 2015, thus leading to a 380% increase in OP to Rs 8.69 crore. Interest costs stood at Rs 0.66 crore down by 9% and depreciation was up by 3% to Rs 1.19 crore. After providing total tax of Rs 1.63 crore, PAT for FY 2016 stood at Rs 5.31 crore. On equity share capital of Rs 38.37 crore of face value of Rs 10 each, EPS for FY 2016 works out to Rs 1.4. At a higher price band of Rs 80 per equity share, the scrip is offered at P/E multiple of 57.8.
10.1. Khemka  Nov 9, 2016 10:28:24 AM IST
By Popular Stock Brokers
ProStocks, The Flat Rate Discount Stock Broker
Flat Fee Broker

Rs 899 Unlimited Equity
Rs 499 Unlimited Curr
or Rs 15 per Trade

Lowest Transaction Charge
Lowest Call & Trade Fee
Lowest Stamp Duty

FREE Trading + Demat Acct

Flat Rs 20 Per Trade
Free Equity Delivery Trades

Rs 100 off on account opening* + 100% brokerage refund if in 60 days you have made net profits

Enquire Now
(* on online account opening)

Intraday @ 0.02%
Delivery @ 0.15%

Rs 0 account opening fee
(Rs 400 waived)

Request Demo

RKSV Discount Broker  RKSV

Ditch & Switch

Switch to RKSV and earn brokerage credit of Rs 2000

Get RKSV Trading Account

Beginner, seasoned investor, active trader or HNI. Get customised solutions.

Rs 0 account opening fee on Online Trading + Demat Acct
(Rs 1150 waived)

Request Call Back

More About Brokers

Special Offers Broker Reports

Message Board

Stock Message Board